LRIG1 expression in colorectal cancer
LRIG1 expression in colorectal cancer
复制标题
DOI：
10.1080/02841860701426823
复制
发表时间：
2007-01-01
期刊：
影响因子：
3.1
通讯作者：
Malmer, Beatrice
中科院分区：
文献类型：
--
作者：
Ljuslinder, Ingrid;Golovleva, Irina;Malmer, Beatrice
本研究检测了30例结直肠癌患者肿瘤组织和癌旁非肿瘤组织中亮氨酸重复序列和免疫球蛋白样域1(LRIG1)的表达及其与表皮生长因子受体(EGFR)的关系。位于染色体3p14的LRIG1基因编码一个整合膜蛋白，该蛋白通过属于ERBB(表皮生长因子受体)家族的受体酪氨酸激酶来抵消信号。到目前为止，LRIG1在所有被分析的组织和器官中都有表达，包括乳房、脑、皮肤、肾脏、脾和结肠。EGFR的过度表达见于70-90%的结直肠癌，并与较差的生存率有关。Western印迹分析显示，与邻近的非肿瘤组织相比，43%的结直肠癌组织中LRIG1表达上调，43%的结直肠癌组织中LRIG1表达下调。Western Blot分析的LRIG1与免疫组织化学分析的EGFR表达之间无明显相关性。FISH(荧光原位杂交)分析显示，9个肿瘤中有1个的LRIG1拷贝数增加。4株结直肠癌细胞系均有两个LRIG1基因拷贝。结论：LRIG1蛋白在结直肠癌中的表达存在很大的异质性，与LRIG1基因的基因剂量无关。进一步的研究将有助于评估LRIG1在结直肠癌中的表达变化是否具有生物学或临床意义。
In the present study the expression of LRIG1 (leucine rich repeats and immunoglobin-like domains 1) and its relation to EGFR (epidermal growth factor receptor) was examined in tumour samples and adjacent non-neoplastic tissues from 30 patients with colorectal cancer. The LRIG1 gene, at chromosome 3p14, encodes an intergral membrane protein, which counteracts signalling by receptor tyrosine kinases belonging to the ERBB (epidermal growth factor receptor) family. LRIG1 is expressed in all tissues and organs analysed to date, including breast, brain, skin, kidney, spleen and colon. Overexpression of EGFR is seen in 70 - 90% of colorectal cancers, and is associated with a poor survival. Western blot analysis showed LRIG1 upregulation in 43% and downregulation in 43% of the colorectal cancers compared to adjacent non-neoplastic tissue. No correlation was evident between LRIG1, analysed by Western Blot and the expression of EGFR analysed by immunohistochemistry. FISH (fluoroscence in situ hybridisation) analysis showed increased LRIG1 copy number in one of nine tumours. Four colorectal cancer cell lines demonstrated two LRIG1 gene copies. In conclusion, there was a great heterogeneity in the expression of the LRIG1 protein in colorectal cancer, which was not related to gene dosage of the LRIG1 gene. Further studies can be of interest to evaluate whether alteration in LRIG1 expression in colorectal cancer is of biological or clinical significance.